Table 1 Baseline characteristics (n = 15)
ADT (n = 5) | TOPADT (n = 5) | P value (vs. ADT) | RAPADT (n = 5) | P value (vs. ADT) | ||
|---|---|---|---|---|---|---|
Age (median, range) | 76 (74–85) | 73 (63–81) | 0.59 | 72 (67–75) | 0.29 | |
PSA (ng/mL) (median, range) | 223 (30.6–8428) | 264 (30–818) | 1 | 126 (30.8–3600) | 0.83 | |
Gleason score | 7 | 1 | 0 | 0.72 | 2 | 0.57 |
8 | 2 | 2 | 1 | |||
9 | 1 | 2 | 2 | |||
10 | 1 | 1 | 0 | |||
Clinical T stage | 2c | 2 | 4 | 0.19 | 2 | 0.55 |
3a | 3 | 1 | 2 | |||
3b | 0 | 0 | 0 | |||
4 | 0 | 0 | 1 | |||
Clinical N stage | 0 | 2 | 4 | 0.19 | 1 | 1 |
1 | 3 | 1 | 4 | |||
Clinical M stage | 1b | 5 | 4 | 1 | 5 | 1 |
1c | 0 | 1: lung | 0 | |||
Extent of disease | 1 | 4 | 3 | 0.49 | 4 | 1 |
2 | 0 | 2 | 1 | |||
3 | 1 | 0 | 0 | |||
J-CAPRA score (median, range) | 9 (8–10) | 8 (7–9) | 0.37 | 9 (6–11) | 0.92 | |
Labeling index (median, range) | ||||||
AR | 78.5 (54.8–100) | 87.1 (30–100) | 1 | 100 (37.5–100) | 0.68 | |
ERα | 27.9 (0–46.5) | 19.7 (0–37.4) | 0.34 | 20.6 (13.4–35.4) | 0.54 | |
ERβ | 20.3 (2.4–44.9) | 11.9 (7.4–91.4) | 0.75 | 15.2 (7–26.4) | 0.9 | |